Epion Therapeutics</a> (Copy)
1 known investors
Epion Therapeutics is developing EpiSmart, a minimally-invasive corneal cross-linking system to treat keratoconus and corneal ectasia without disrupting the epithelium. The treatment targets patients with ectatic corneal disease as an early-intervention standard of care.